EUCTR2008-007877-19-DE进行中（未招募）不适用
asale Inhalation von Colistin mit dem Pari-Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich.Nasal inhalation of colistin by the Pari Sinus nebulizer im patients with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways. - colistin nasal CF pilot
niversity of Jena0 个研究点目标入组 14 人开始时间: 2009年5月28日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject has a confirmed diagnosis of cystic fibrosis based on:
- •3 positive sweat chloride tests and/or genetic characterisation
- •2. detection of P. aeruginosa in nasal lavage (culture) with chronic P.
- •aeruginosa colonization of the lung (from day – 28)
- •3. informed consent of the patients or parents
- •4. Subject >= 6 years
- •5. Subject is able to comply with the inhalation procedures and nasal
- •lavage procedures scheduled in the protocol.
- •6. Women of childbearing potential are only included into the study, if they
- •are using an effective method of birth control during the protocol (e.g.
- •implants, combined oral contraceptives, injectables, some IUDs, sexual
- •abstinence or vasectomised partner)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.subject has a critical condition defined as:
- •FEV1 < 30% and / or
- •SaO2 < 93% without O2-substitution; need of O2-substitution
- •2.Subject had an ENT surgery within 3 months prior to study
- •3.Subject shows signs of nasal bleeding
- •4.Subject has an ear drum perforation
- •5.Subject had an acute rhinosinusitis or a pulmonary exacerbation at study
- •entry with need of additional systemic antibiotic therapy against
- •pseudomonas aerug.
- •6.Subject is unlikely to comply with the procedures scheduled in the protocol
- •7.Subject has contraindications and known side effects to the medication
- •8.Subject is pregnant or breastfeeding
- •9.Subject participates in another clinical trial within 30 days prior to study
- •entry or 30 days after end of the study.
- •10.Systemic (oral or intravenous) antibiotic treatment against P.a. 14 days
- •prior to the inclusion and during the study
研究者
相似试验
进行中（未招募）
不适用
asale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich.Nasal inhalation of tobramycin by the Pari Sinus nebulizer in patients with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways. - tobra nasal CF pilotsubjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airwaysEUCTR2008-000164-17-DEniversity of Jena14
尚未招募
4 期
Comparison of antibiotics given through vein only versus antibiotics given through vein and nebulization for treating patients who develop pneumonia while being on ventilatorCTRI/2024/07/070092All India Institute Of Medical SciencesNew Delhi
已完成
2 期
Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa ColonizationPseudomonas AeruginosaCystic FibrosisNCT01035853University of Jena10
已完成
2 期
Effect of Inhaled Colistin on the Treatment of Pulmonary Infections Caused by Ventilator with Multi-drug Resistant Acinetobacter at in Intensive Care Unit of Rasoul-Akram Hospital in 2016-17Pulmonary infection Caused by Ventilator.Pulmonary mycobacterial infectionIRCT2017091236068N1Vice chancellor for Research and Technology of Iran University of Medical Sciences114
招募中
不适用
se of surfactant with corticosteroids to prevent chronic lung disease in premature infantsBronchopulmonary dysplasia originating in the perinatal periodP27.1RBR-72kkgcHospital das Clínicas da Universidade Federal de Goiás